结直肠癌
卡培他滨
免疫组织化学
癌胚抗原
H&E染色
医学
染色
癌症
原发性肿瘤
病理
肿瘤科
癌症研究
内科学
转移
作者
Yutao Zhang,Yong-ming Yao,Likun Zan,Jing Wang,Yan Lei,Lili Zhao,Lixia Chen,Yanfeng Xi,Wenqi Bai,Xihua Yang
出处
期刊:DOAJ: Directory of Open Access Journals - DOAJ
日期:2023-02-01
卷期号:26 (2): 248-254
标识
DOI:10.22038/ijbms.2022.67445.14780
摘要
Patient-derived xenograft (PDX) model becomes a more and more important tool for tumor research. This study aimed to establish a colorectal cancer PDX model and verify its applicability.Fresh human colorectal cancer tissue was surgically removed and subcutaneously inoculated into immunodeficient mice to establish the PDX model. Hematoxylin and eosin (HE) staining and immunohistochemical staining were used to evaluate the model. The successful PDX model was selected to study the efficacy of capecitabine in treating colorectal cancer.HE staining showed that the PDX mice model of colorectal cancer could preserve the histological characteristics of the primary tumor. Immunohistochemistry staining showed α-fetoprotein (AFP), carcinoembryonic antigen (CEA), and E-cadherin were strongly positively expressed in primary human and PDX tumor tissues, with a high degree of similarity. Capecitabine significantly inhibited PDX tumor growth and reduced the expression of AFP and CEA proteins in the tumor tissues (all Ps<0.05).We successfully established a colorectal cancer PDX model, and the PDX model could retain the histological and biological characteristics of the primary tumor. Using this PDX model, we revealed that capecitabine at a dose of 300-400 mg/kg can effectively treat colorectal cancer, and no significant difference in toxicity was found among different dose groups. The current work provides a feasible framework for establishing and validating the PDX tumor model to better facilitate the evaluation of drug efficacy and safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI